Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acoramidis in Symptomatic Transthyretin Amyloid Cardiomyopathy
NCT03860935Phase 3Completed
- Sponsor
- BridgeBio Pharma
- Start
- Mar 2019
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by BridgeBio Pharma. Started Mar 2019; status: completed.
02
Drugs
acoramidis
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT03860935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03860935.